The Correlation Between Lung Cancer Susceptibility, Drug Response and Genetic Polymorphism

NCT01280448 | Unknown

• 1 other identifier: 99054
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

Lung cancer is the leading cause of cancer deaths in Taiwan. The carcinogen in the environment is a key role in the development of lung cancer, and one of its main resource is tobacco. Activated carcinogens in the organism lead to mutations of crucial oncogenes resulting in tumor development. Genes such as Cytochrome P-450 family, GST (glutathione S-transferase) family, UGT (UDP-Glucuronosyltransferase) family, ERCC-1(excision repair cross-complementing rodent repair deficiency),ERCC-4 and ERCC-5,are encoding antioxidant enzymes or involving in the DNA repair process and the production of some transcription factors. In recent years, many studies have shown the correlation between these genes and the susceptibility of lung cancer. Each gene has a different role in the tumor development pathway. CYP, UGT, GST, NAT2 (N-acetyltransferase 2) and NQO1(NAD(P)H:quinono oxidoreductase 1) involve in the production of antioxidant enzymes. The antioxidant enzymes can detoxificate hydrogen peroxide or defense against oxidative stress. However, the genetic polymorphisms may influence the function of detoxification, which cause the increase in the susceptibility of lung cancer. P53 and MDM2 genes play important roles in the production of tumor-suppression proteins and the regulation of transcription factors, which may regulate the growth and the apoptosis of cell cycle and influence the susceptibility of lug cancer. The polymorphisms in ERCC genes may cause the damage in the DNA repair process which might also cause increase in lung cancer susceptibility. The overexpression of epidermal growth factor receptor is highly correlated with increasing risk of the non-small cell lung cancers. The overexpression may induce the proliferation of cancer cells and the inhibition of the apatosis. Therefore, in recent years, EGFR has been widely studied as the new target of the drugs and the susceptibility of the lung cancer. In addition,the genetic polymorphisms in drug metabolism channel proteins, like OCT2 (organic cation transporter), ATP7A, ATP7B and ABC (ATP-binding cassette) transporter may have influence on the metabolism, the efficacy and the toxicity of the drugs.

Conditions

Lung Cancer

Keywords

Lung Cancer; Tobacco Smoking; gene polymorphism

Study Arms (2)

Case Group

Control Group

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Lung Cancer patients

You may qualify if:

• This study has two groups, the case group and the control group. The match criteria is patients with the same gender and the age is ± 5 years.
• Case group - Patients with the pathology diagnosed as the primary lung cancer patients.
• Control group - Patients without any cancer or disease history of cancers.

You may not qualify if:

• Case group - Patients with the pathology diagnosed as the non-primary lung cancer patients or the patients with lung cancer induced by other cancer metastasis.
• Control group -
• With other cancers.
• With COPD induced by smoking or the genetic factors.
• With familial adenomatous polyposis
• With HIV infection, hepatitis B or hepatitis C

Sponsors & Collaborators

• Taipei Medical University WanFang Hospital: lead

Study Sites (1)

Taipei Medical University - WanFang Hospital

Taipei, Taiwan

Location

Biospecimen

Retention: SAMPLES WITH DNA

genes

MeSH Terms

Conditions

Lung Neoplasms; Tobacco Smoking

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Smoking; Behavior; Tobacco Use

Study Officials

• Hsin-Gjin Eugene Liu

  Taipei Medical University WanFang Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: January 19, 2011
• First Posted: January 20, 2011
• Study Start: September 1, 2010
• Study Completion: September 1, 2013
• Last Updated: January 20, 2011

Record last verified: 2011-01

Locations

TW (1)